Sanofi Ventures — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus, with a lead candidate (AlpN GBS) in clinical trials for use in pregnancy and older adults.
BiotechHealthtech
Co-investorsAdjuvant CapitalIndustrifondenLU InnovationOrbiMedPureos BioventuresSunstone Capital+2 more
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSV Health InvestorsAmgen Ventures+6 more
Therini Bio is a biotechnology company developing therapies that block vascular-mediated inflammation to halt chronic neurological disease.
BiotechHealthtechSacramento, US
Laia Crespo-Martin(Director)Leslie Schulze(Executive Officer)Daniel D Burgess(Director)Michael Ross(Director)Tara Nickerson(Executive Officer, Director)
BoardOlga Danilchanka(Director)
Co-investorsAngelini VenturesMitsui Global InvestmentMRL Ventures FundSV Health InvestorsApollo Health VenturesDementia Discovery Fund+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.